Description
Product Overview
Kadcyla® 100mg Injection is an advanced targeted anti-cancer biologic therapy containing Trastuzumab Emtansine (T-DM1), a recombinant monoclonal antibody linked to a potent cytotoxic agent. Developed by Roche / Genentech, Kadcyla is specifically designed for the treatment of HER2-positive metastatic breast cancer, helping target cancer cells directly while minimizing damage to healthy cells.
This antibody–drug conjugate combines the HER2-targeting ability of trastuzumab with the anti-cancer activity of DM1 emtansine, allowing precise delivery of chemotherapy directly into cancer cells. Kadcyla is widely used in oncology treatment centers and hospitals worldwide for advanced breast cancer management.
Product Details
| Attribute | Information |
|---|---|
| Brand Name | Kadcyla® / Survanta |
| Generic Name | Trastuzumab Emtansine (T-DM1) |
| Strength | 100mg |
| Dosage Form | Injection |
| Type | Antibody–Drug Conjugate / Targeted Anti-Cancer Therapy |
| Packaging | Single-Use Vial |
| Appearance | White to Pale Yellow Lyophilized Powder |
| Material | Recombinant Monoclonal Antibody + DM1 Cytotoxic Agent |
| Manufacturer | Roche / Genentech |
| Country of Origin | India |
| Supply Type | Exporter, Distributor |
| Administration Route | Intravenous (IV) Infusion |
Medical Uses
Kadcyla® 100mg Injection is primarily used for:
- HER2-Positive Metastatic Breast Cancer
- Advanced HER2-Positive Breast Cancer
- Residual Invasive HER2-Positive Breast Cancer after prior therapy
- Oncology-targeted biologic treatment protocols
This medication helps slow cancer progression, reduce tumor growth, and improve treatment response in eligible patients.
Mechanism of Action
Kadcyla works by specifically targeting the HER2 protein present on certain breast cancer cells. Once attached to the cancer cell, the medication delivers the cytotoxic DM1 agent directly into the tumor cell, disrupting its growth and causing cancer cell death while reducing effects on healthy tissue.
Dosage & Administration
- Administered intravenously under professional medical supervision
- Typically given once every 3 weeks
- Infusion duration may range between 30–90 minutes
- Dosage and treatment schedule depend on patient condition and oncologist recommendation
Patients should attend all scheduled treatment sessions for maximum therapeutic benefit.
Possible Side Effects
Common Side Effects
- Fatigue
- Nausea and vomiting
- Headache
- Constipation
- Muscle and joint pain
- Mild liver enzyme elevation
Serious Side Effects
- Liver complications
- Heart-related issues
- Severe infusion reactions
- Lung complications
- Bleeding disorders
Patients should immediately report unusual symptoms to their healthcare provider.
Important Safety Information
- Not recommended during pregnancy
- Effective contraception is advised during and after treatment
- Avoid breastfeeding during therapy
- Liver and heart function monitoring are required during treatment
- Use strictly under oncologist supervision
Why Choose Kadcyla®?
✔ Advanced HER2-targeted cancer therapy
✔ Trusted Roche / Genentech formulation
✔ Precision oncology biologic treatment
✔ Worldwide pharmaceutical supply available
✔ Suitable for hospitals, oncology clinics, and distributors
✔ Secure cold-chain packaging and export support
Reviews
There are no reviews yet.